Changes in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy

Journal of Ultrasound in Medicine

Volumn 25, Issue 4, 2006, Pages 469-473

  Fishman, Mindy ^a   Boda, Mona ^a   Sheiner, Eyal ^b,c   Rotmensch, Jacob ^b   Abramowicz, Jacques ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Breast cancer; Endometrium; Sonography; Tamoxifen

Indexed keywords

DRUG DOSAGE; MEDICINE; PATIENT TREATMENT; REGRESSION ANALYSIS; STATISTICAL METHODS;

BREAST CANCER; ENDOMETRIAL THICKNESS; PATIENTS WITH BREAST CANCER; SONOGRAPHY; TAMOXIFENS;

ULTRASONIC MEASUREMENT;

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DATA BASE; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOMETRIUM; ETHNOLOGY; FEMALE; GRAVITY; HUMAN; IMAGE ANALYSIS; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PARITY; STATISTICAL ANALYSIS; UNITED STATES; UTERUS; WEIGHT;

EID: 33646066284     PISSN: 02784297     EISSN: None     Source Type: Journal    
DOI: 10.7863/jum.2006.25.4.469     Document Type: Article

References (18)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Colditz GA. Epidemiology and prevention of breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:768-772.
3. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353:1993-2000.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J National Cancer Inst 1998; 90:1371-1388.
5. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002; 360:817-824.
6. Machado F, Rodriguez JR, Leon JP, Rodriguez JR, Parrilla JJ, Abad L. Tamoxifen and endometrial cancer: is screening necessary? A review of the literature. Eur J Gynaecol Oncol 2005; 26:257-265.
7. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296-300.
8. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170:447-451.
9. Goldstein SR. Controversy about uterine effects and safety of SERMs: the saga continues. Menopause 2002; 9:381-384.
10. McGonigle K, Shaw S, Vasilev S, Odom-Maryon T, Roy S, Simpson J. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998; 178:1145-1150.
11. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17:2050-2054.
12. American College of Obstetricians and Gynecologists. ACOG practice bulletin: selective estrogen receptor modulators. Number 39, October 2002. Int J Gynaecol Obstet 2002; 79:289-298.
13. Cohen I, Rosen DJ, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994; 52:185-190.
14. Weaver J, McHugo JM, Clark TJ. Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen. Br J Radiol 2005; 78:394-397.
15. Markovitch O, Tepper R, Fishman A, Shapira J, Aviram R, Cohen I. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 2004; 95:456-462.
16. McGonigle KF, Lantry SA, Odom-Maryon TL, Chai A, Vasilev SA, Simpson JF. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Lett 1996; 101:59-66.
17. Cohen I, Beyth Y, Azaria R, Flex D, Figer A, Tepper R. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in post-menopausal breast cancer patients. BJOG 2000; 107:1083-1087.
18. Menada MV, Papadia A, Lorenzi P, Costantini S, Bertelli GF, Ragni N. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 2004; 25:321-323.